1. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)
- Author
-
Belderbos, José, Uitterhoeve, Lon, van Zandwijk, Nico, Belderbos, Huub, Rodrigus, Patrick, van de Vaart, Paul, Price, Allan, van Walree, Nico, Legrand, Catherine, Dussenne, Sonia, Bartelink, Harry, Giaccone, Giuseppe, and Koning, Caro
- Subjects
- *
DRUG therapy , *RADIOTHERAPY , *SMALL cell lung cancer , *LUNG cancer , *CANCER patients - Abstract
Abstract: A randomised phase III study was performed comparing sequential (S) and concurrent (C) chemo-radiotherapy (CRT) in non-small cell lung cancer (NSCLC) patients. Methods: One hundred and fifty-eight patients were randomised to receive two courses of Gemcitabine (1250mg/m2 days 1, 8) and Cisplatin (75mg/m2 day 2) prior to, or daily low-dose Cisplatin (6mg/m2) concurrent with radiotherapy, consisting of 24 fractions of 2.75Gy in 32 days, with a total dose of 66Gy. Results: Acute haematological toxicity grade 3/4 was more pronounced in the sequential (S) (30% versus 6%), oesophagitis grade 3/4 more frequent in the concurrent (C) arm (5% versus 14%). Late oesophagitis grade 3 was 4% (S and C), pneumonitis grade 3/4 14% (S) and 18% (C). Because of the poor power of the study no significant differences in median survival (MS), overall survival (OS) and progression-free survival (PFS) could be detected. MS was 16.2 (S) and 16.5 (C) months, 2-year OS was 34% (S) and 39% (C), 3-year OS was 22% (S) and 34% (C). Conclusion: Radiotherapy 66Gy given concurrently with daily low-dose Cisplatin or after two courses of Gemcitabine/Cisplatin was well tolerated. Due to early closure no conclusions can be reached on the relative merits; both arms showed good OS. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF